Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
/in Dendritic Cells, Glioblastoma, International Publications, Malignant MelanomaCombination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
/in Dendritic Cells, Glioblastoma, International PublicationsThe Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsAutologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality
/in Dendritic Cells, Glioblastoma, International PublicationsIndividualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
/in Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenGlioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus[Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma]
/in Dendritic Cells, Glioblastoma, International PublicationsAssociation of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
/in Dendritic Cells, Glioblastoma, International PublicationsAutologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer